Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280191 | 0.95 | DGAT1 (0.33) | DGAT1NSD2 | |
| SCHEMBL2278551 | 0.94 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL2279196 | 0.91 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL2275312 | 0.91 | TYRO3 (0.33) | DGAT1 | |
| SCHEMBL2277267 | 0.90 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL2278197 | 0.87 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL2272755 | 0.87 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL2278452 | 0.83 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL2273709 | 0.83 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL2281494 | 0.83 | PRKCI (0.40) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | DGAT1 4740/4885NSD2 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.